Because of these and other functions, CAFs have been historically labeled as tumor-promoting cells; however, therapeutic targeting of the αSMA+ CAFs has not demonstrated significant benefits in inhibiting tumor growth8,9, while FAP targeting strategies such as the use of CAR-T have been inconclusive10–14. Here, ACTA1 is linked to neoplasm.